{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:19:08Z","timestamp":1789611548646,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC-2026-2801297"],"award-info":[{"award-number":["RC-2026-2801297"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Invasive fungal diseases (IFDs) are a major threat in pediatric patients with hematologic malignancies (HMs) and hematopoietic stem cell transplantation (HSCT) recipients. Optimal antifungal prophylaxis (AFP) remains a clinical challenge. Isavuconazole (ISA), a broad-spectrum triazole, may offer a safer, more predictable option for AFP in this setting, but pediatric data are scarce. We retrospectively analyzed pediatric patients (\u226418 years) with HM or HSCT who received isavuconazole as primary AFP from January 2021 to April 2025 at a single center. Isavuconazole dosing, therapeutic drug monitoring (TDM), safety, and breakthrough IFD incidence were systematically evaluated in a standardized stewardship framework. Isavuconazole was administered as primary antifungal prophylaxis in 21 patients (median age 9.6 years), 17 (77.3 %) after HSCT. Doses were weight-adjusted (100 or 200 mg\/day) with loading over 48 h. No severe adverse events attributable to isavuconazole were reported. No breakthrough IFDs occurred during prophylaxis. Concomitant use of CYP3A4-interacting agents (e.g., ruxolitinib) was not associated with increased toxicity or isavuconazole level alterations. TDM was performed in all patients (188 total measurements); median Cmin was 3.4 mg\/L. The target range (1\u20135 mg\/L) was achieved in 95.2% of first TDMs. Dosage adjustments were needed in only 5.9% of cases, indicating consistent pharmacokinetics. In this retrospective cohort of high-risk pediatric hematology patients, isavuconazole used as primary antifungal prophylaxis showed favorable safety, consistent drug exposure, and no breakthrough IFDs. These findings support further prospective evaluation of isavuconazole in pediatric prophylactic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00451-26","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:57:07Z","timestamp":1782482227000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis"],"prefix":"10.1128","volume":"70","author":[{"given":"Francesco","family":"Baccelli","sequence":"first","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Campoli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4771-9808","authenticated-orcid":true,"given":"Martina","family":"Colli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":true,"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gottardi","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Venturelli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Leardini","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Muratore","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Boss\u00f9","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Azienda Unit\u00e0 Sanitaria Locale di Rimini","place":["Rimini, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":true,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Belotti","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Prete","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000980"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30723-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01768-x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154545"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof9020166"},{"key":"e_1_3_3_8_2","volume-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications","author":"Autmizguine J","year":"2014","unstructured":"Autmizguine J, Guptill JT, Cohen-Wolkowiez M, Benjamin DK, Capparelli EV. 2014. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Springer International Publishing."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003659"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101316"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2022.101310"},{"key":"e_1_3_3_12_2","unstructured":"CHMP. 2024 Cresemba INN-isavuconazole. Available from: www.ema.europa.eu\/contact"},{"key":"e_1_3_3_13_2","unstructured":"fda and cder. 2024 Highlights of prescribing information. Available from: www.fda.gov\/medwatch"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00484-24"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf394"},{"key":"e_1_3_3_16_2","unstructured":"European Medicines Agency. 2015. European Public Assesment Report (EPAR) Cresemba"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Ross JA. 2020. Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience. Available from: www.jpho-online.com","DOI":"10.1097\/MPH.0000000000001787"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00177-22"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00829-23"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof8010074"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030375"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29807"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01783-19"},{"key":"e_1_3_3_24_2","unstructured":"European Medicines Agency. 2024 European public assessment report (EPAR) cresemba. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/ EPAR\/cresemba"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000547799"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-21"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13622"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1751"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-018-0287-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0273-7"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22972"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02158.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02252-z"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00740-5"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010113"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93571-4"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae139"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad086"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12071388"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00451-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00451-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:02:59Z","timestamp":1785848579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00451-26"}},"subtitle":[],"editor":[{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["10.1128\/aac.00451-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00451-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00451-26"}}